Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes
2005 ◽
Vol 46
(5)
◽
pp. 821-826
◽
Hussam Abuissa
◽
Philip G. Jones
◽
Steven P. Marso
◽
James H. O’Keefe
2019 ◽
Vol 37
(1)
◽
pp. 44-52
◽
C. I. Coleman
◽
E. R. Weeda
◽
A. Kharat
◽
B. Bookhart
◽
W. L. Baker
2002 ◽
Vol 4
(3)
◽
pp. 185-190
◽
Jay Garg
◽
George L. Bakris
2019 ◽
Vol 68
(Supplement 1)
◽
pp. 1150-P
CRAIG I. COLEMAN
◽
ERIN R. WEEDA
◽
AKSHAY A. KHARAT
◽
BRAHIM BOOKHART
◽
WILLIAM L. BAKER
2013 ◽
Vol 19
(4)
◽
pp. 579-586
◽
Nasreen AL-Sayed
◽
Tianming Gao
◽
Brian Wells
◽
Changhong Yu
◽
Robert Zimmerman
Sirima Mongkolsomlit
◽
Petch Rawdaree
◽
Chulalux Komoltri
2018 ◽
Vol 42
(2)
◽
pp. 118-123
◽
Thomas A. Mavrakanas
◽
Mark L. Lipman
2009 ◽
Vol 33
(5)
◽
pp. 391-395
◽
E.R. Koomen
◽
R.M.C. Herings
◽
H.J. Guchelaar
◽
T. Nijsten
2012 ◽
Vol 14
(10)
◽
pp. 731-731
◽
John J.V. McMurray
◽
Robert M. Califf
◽
Angelyn M. Bethel
◽
Steven M. Haffner
◽
Rury R. Holman
2004 ◽
Vol 148
(5)
◽
pp. 747-754
◽
Sverre E. Kjeldsen
◽
Stevo Julius